Boaz Brill

Boaz Brill is an experienced leader in the fields of precision medicine and technology development, currently serving as CEO of Pentaomix since March 2021, where the focus is on creating a system that provides detailed biomarker analysis for cancer patients, utilizing artificial intelligence for drug response correlation. Previously, Boaz Brill held the CEO position at GluSense Medical, developing innovative continuous glucose sensors for diabetes management, and served as CTO and VP for Technology Development at Nova Measuring Instruments, overseeing metrology solutions for the semiconductor industry and leading significant R&D efforts. Early career roles included system engineering at El-Op electro-optics industries and physicist team leadership at Soreq NRC. Boaz Brill holds a Ph.D. in Condensed Matter Physics from the Weizmann Institute of Science, an MBA from the University of Bradford, and a B.Sc. in Physics and Mathematics from Talpiot at The Hebrew University.